Denosumab treatment for three years fully reversed this bone loss, and two additional years of treatment resulted in further BMD gains that translated to significantly lower wristfracture rates.
With two additional years of denusomab treatment, their bone mineral density increased further and the wristfracture rate declined to levels significantly lower than the FREEDOM placebo rate (rate ratio = 0.57, 95 % CI = 0.34 - 0.95; p = 0.03).